Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Posted: 3 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line…
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Posted: 3 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the INSIGHT-003…
Surgery game-changer
Posted: 31 March 2023 St Vincent’s Hospital Melbourne has become the first public hospital in Australia to install the Synaptive Modus V – a robotic exoscope powered by artificial intelligence voice control that provides surgical teams with 3D…
Networking the Monash research and innovation ecosystem
Posted: 31 March 2023 Last week, Mr Matt Fregon MP, Victorian Member for Ashwood, officially launched the Monash Precinct Network, which will further accelerate the growth of the City of Monash as an international destination of global research…
Atmo Biosciences closes fully subscribed $8 million Series B funding round
Posted: 31 March 2023 Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, has raised A$8 million in a fully subscribed Series B funding round. The raise…
Noxopharm Announces Novel mRNA Vaccine Enhancer
Posted: 29 March 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces the development of a new proprietary product candidate based on mRNA technology as part of the company’s SofraTM preclinical platform. A lead candidate has now been selected…
GeneType Multi-Test Panel Expanded: Inclusion of 3 New D iseases
Posted: 28 March 2023 Genetic Technologies Limited – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the initiation of phase 2 of the rollout plan for the geneType Multi-Test.…
Imagion to proceed to file an IND for the MagSense® HER2 Imaging Agent following FDA feedback
Posted: 28 March 2023 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update on development plans for its MagSense® HER2 imaging agent. Based on feedback the…
US FDA clearance of Adherium’s Hailie for Teva inhalers
Posted: 24 March 2023 Adherium Limited, a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market application, connecting Teva Pharmaceutical…
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Posted: 23 March 2023 Firebrick Pharma Limited is pleased to announce that its Phase 3 clinical trial of Nasodine Nasal Spray (Nasodine) as a treatment for the common cold has received the necessary ethics approvals to re-open for…
ANDHealth Announces Partnership with Brandon BioCatalyst for $50m BioMedtech Incubator
Posted: 21 March 2023 We are delighted to announce that, ANDHealth, in partnership with Brandon BioCatalyst, has been selected by the Medical Research Future Fund to deliver the $50m BioMedTech Incubator Program (BMTI). This investment substantially increases the combined non-dilutive…
FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy
Posted: 17 March 2023 Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable…
